ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1890

Use of Artificial Intelligence to Diagnose Polymyalgia Rheumatica on 18F-FDG Whole Body PET/CT in Patients with Atypical Clinical Features

Emily Martin1, Christopher McMaster1, Saskia Rowson1, Victor Yang1, Aurora Poon1, Bonnia Liu1, Jessica Leung2, Andrew Scott1, David Liew1 and Claire Owen3, 1Austin Health, Heidelberg, Australia, 2Austin Health, Preston, Australia, 3Austin Health, Malvern East, Australia

Meeting: ACR Convergence 2023

Keywords: Nuclear Medicine, Polymyalgia Rheumatica (PMR)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1862–1894) Imaging of Rheumatic Diseases Poster II

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: PET/CT is a highly sensitive and specific test for diagnosing PMR.(1) This study investigated the utility of 18F-FDG whole body PET/CT in patients presenting with atypical clinical features and tested the performance of a novel artificial intelligence (AI) algorithm to simplify PMR diagnosis.

Methods: PET/CT reports from January 2015 to current were searched for findings suggestive of PMR using natural language processing. The scanned medical record of each identified case was reviewed to determine the final clinical diagnosis. Required criteria per the 2012 EULAR/ACR PMR Classification Criteria(2) (age ≥50 years, bilateral shoulder aching and abnormal CRP +/ ESR) were recorded, with patients not meeting these considered “atypical”. Qualitative and semi-quantitative (SUVmax) PET/CT scores of steroid-naïve atypical PMR patients were compared with an existing typical steroid-naïve PMR population. Differences in 18F-FDG avidity (mean SUVmax) were examined at key musculoskeletal sites. The performance of a ResNet50 AI model trained on PET/CT images of typical PMR and large joint arthritis patients was tested on the atypical PMR cohort. GradCam maps were employed to cross-check the AI’s focus on characteristic PMR-involved anatomical regions.

Results: 225 PET/CT reports were retrieved from >38,000 scans, with 121 patients possessing a final clinical PMR diagnosis. 17 steroid-naïve atypical patients were compared with 35 steroid-naïve typical cases. Mean CRP (10.1±20.9 cf. 44.0±32.9 [p=0.0002]) and ESR (11.5±7.2 cf. 49.3±29.6 [p=0.0001]) were lower in the atypical group, but the frequency of abnormalities at key musculoskeletal sites was similar (Table 1). A statistically significant difference (p < 0.05) in mean SUVmax was detected between the groups at every musculoskeletal site analyzed. When the novel AI-trained model was tested on PET/CT images of atypical patients, 16/17 were identified as positive for a PMR diagnosis. Figure 1 provides a GradCam map example in an atypical PMR case.

Conclusion: PMR patients with atypical clinical features exhibit the same PET/CT abnormalities as typical cases, but affected musculoskeletal sites are less 18F-FDG avid. This distinctive imaging pattern can be harnessed by AI technology to facilitate PMR diagnosis in challenging clinical scenarios.

References:
1. Owen CE, Poon AMT, Yang V, McMaster C, Lee ST, Liew DFL, et al. Abnormalities at three musculoskeletal sites on whole-body positron emission tomography/computed tomography can diagnose polymyalgia rheumatica with high sensitivity and specificity. Eur J Nucl Med Mol Imaging. 2020. 2. Dasgupta B, Cimmino MA, Kremers HM, Schmidt WA, Schirmer M, Salvarani C, et al. 2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheumatol. 2012;64(4):943-54.

Supporting image 1

Table 1: Frequency and 18F-FDG avidity of key musculoskeletal site abnormalities in atypical compared with typical PMR patients.

Supporting image 2

Figure 1: An example GradCam map highlights areas of the PET/CT image that contributed to a positive PMR diagnosis. This patient had bilateral shoulder and posteromedial knee symptoms – the GradCam map shows high intensity in these regions.


Disclosures: E. Martin: None; C. McMaster: None; S. Rowson: None; V. Yang: None; A. Poon: None; B. Liu: None; J. Leung: AbbVie, 1, 6, Eli Lilly, 1, 6, Novartis, 6; A. Scott: None; D. Liew: None; C. Owen: AbbVie/Abbott, 1, 6, Janssen, 6, Novartis, 6.

To cite this abstract in AMA style:

Martin E, McMaster C, Rowson S, Yang V, Poon A, Liu B, Leung J, Scott A, Liew D, Owen C. Use of Artificial Intelligence to Diagnose Polymyalgia Rheumatica on 18F-FDG Whole Body PET/CT in Patients with Atypical Clinical Features [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/use-of-artificial-intelligence-to-diagnose-polymyalgia-rheumatica-on-18f-fdg-whole-body-pet-ct-in-patients-with-atypical-clinical-features/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/use-of-artificial-intelligence-to-diagnose-polymyalgia-rheumatica-on-18f-fdg-whole-body-pet-ct-in-patients-with-atypical-clinical-features/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology